Protherics PLC
Notification of PDMR Interests
London, UK; Brentwood, TN, US; 26 November 2007 - Protherics PLC ("Protherics"
or the "Company"), the international biopharmaceutical company focused on
critical care and cancer, announces that, on 23 November 2007, the following
options over ordinary shares of 2 pence each in Protherics ("Ordinary Shares")
were granted under the terms of the Company's Long Term Incentive Plan:
Name Position Number of
Options
Ian Scoular Director of Business Development 148,837
Nicholas Staples Director of Corporate Affairs 125,581
Sally Waterman Director of Research & Development 148,837
The options are exercisable at a price of 2 pence per share between the third
and tenth anniversary of the date of grant, subject to the achievement of
performance conditions.
Following the above grant, the total number of options held are as follows:
Ian Scoular 1,121,731
Nick Staples 674,744
Sally Waterman 809,210
The current issued ordinary share capital of the Company is 339,696,822 shares.
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
Protherics PLC announces Director/PDMR Shareholding - 2
| Source: Protherics PLC
Cheshire, UK--(Marketwire - November 26, 2007) -